HGF/SF and its receptor c-MET play a minor role in the dissemination of human B-lymphoma cells in SCID mice by Weimar, I S et al.
Disseminating lymphoma cells have to adhere to and cross blood
vessel walls and the underlying matrices of the tissues in which
metastases are formed. Migration of lymphoma cells is thought to
be a multistep process similar to what has been described for
migration of leucocytes at places of inflammation (Tavassali and
Hardley, 1990; Springer, 1994). For transendothelial migration,
different adhesion molecules are important, such as selectins,
CD44 and integrins (Lawrence and Springer, 1991; Carlos and
Harlan, 1994; Zannettino et al, 1995; DeGrendele, 1996). The
latter have to be activated by chemoattractants, which are bound to
endothelial cells. Chemoattractants are important in activating
integrins and in directing the migration of the leucocytes (chemo-
taxis; Berman and Muller, 1996; Butcher and Picker, 1996;
Wakelin et al, 1996). Examples of chemoattractants are platelet-
activating factor (PAF), the complement product C5a, interleukin-
8 (IL-8) and MIP1a (Baggiolini et al, 1994; Strieter et al, 1996;
Adams and Lloyd, 1997). Recently, hepatocyte growth factor
(HGF), also known as scatter factor (SF), was identified as a
chemoattractant for a subset of T-lymphocytes (Adams et al,
1994). HGF/SF is produced by mesenchymal cells and was first
identified as a major mediator of liver regeneration (Michalo-
poulos and Zarnegar, 1989; Nakamura et al, 1989). It also has
mitogenic, morphogenic and motogenic effects on epithelial cells
(e.g. mammary, kidney, intestinal and bronchial epithelial cells) as
well as on endothelial cells (Stoker et al, 1987; Gerardi and Stoker,
1990; Michalopoulos, 1990; Bussolino et al, 1992; Rong et al,
1992, 1993, 1994; Giordano et al, 1993; Grant et al, 1993; Rubin et
al, 1993; Bellusci et al, 1994; Dignass et al, 1994). Recently, a role
has been assigned to HGF/SF in hemopoiesis, since HGF/SF was
found to affect proliferation, adhesion and survival of haemo-
poietic progenitor cells (Kmiecik et al, 1992; Mizuno et al, 1993;
Galimi et al, 1994; Nishino et al, 1995; Zarnegar and Michalo-
poulos, 1995; Goff et al, 1996, 1997; Weimar et al, 1998). The
receptor for HGF/SF is encoded by the MET proto-oncogene, c-
MET, which is a cell surface tyrosine kinase receptor consisting of
an extracellular a- and a transmembrane b-chain with the tyrosine
kinase domain (Giordano et al, 1989; Naldini et al, 1991a, 1991b).
Previous results obtained in our laboratory demonstrated that 
c-MET is expressed in either early or activated normal human 
B-cells as well as in lymph node samples from non-Hodgkin￿s
lymphoma and Hodgkin￿s disease patients. c-MET expression was
also determined in some human B-lymphoma cell lines (two out of
HGF/SF and its receptor c-MET play a minor role in the
dissemination of human B-lymphoma cells in SCID mice
IS Weimar1, K Weijer1, PCM van den Berk1, EJ Muller1, N Miranda1,2, AQ Bakker1, MHM Heemskerk1, A Hekman1, 
GC de Gast1,3 and WR Gerritsen1,3*
1Division of Immunology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2European Cancer Center, Amsterdam, 
The Netherlands; 3Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Summary The MET protooncogene, c-MET, encodes a cell surface tyrosine kinase receptor. The ligand for c-MET is hepatocyte growth
factor (HGF), also known as scatter factor (SF), which is known to affect proliferation and motility of primarily epithelial cells. Recently,
HGF/SF was also shown to affect haemopoiesis. Studies with epithelial and transfected NIH3T3 cells indicated that the HGF/SF–c-MET
interaction promotes invasion in vitro and in vivo. We previously demonstrated that HGF/SF induces adhesion of c-MET-positive B-lymphoma
cells to extracellular matrix molecules, and promoted migration and invasion in in vitro assays. Here, the effect of HGF/SF on tumorigenicity
of c-MET-positive and c-MET-negative human B-lymphoma cell lines was studied in C.B-17 scid/scid (severe combined immune deficient)
mice. Intravenously (i.v.) injected c-MET-positive (BJAB) as well as c-MET-negative (Daudi and Ramos cells) B-lymphoma cells formed
tumours in SCID mice. The B-lymphoma cells invaded different organs, such as liver, kidney, lymph nodes, lung, gonads and the central
nervous system. We assessed the effect of human HGF/SF on the dissemination of the B-lymphoma cells and found that administration of
5 mg HGF/SF to mice, injected (i.v.) with c-MET-positive lymphoma cells, significantly (P = 0.018) increased the number of metastases in lung,
liver and lymph nodes. In addition, HGF/SF did not significantly influence dissemination of c-MET-negative lymphoma cells (P = 0.350 with
Daudi cells and P = 0.353 with Ramos cells). Thus the effect of administration of HGF/SF on invasion of lymphoma cells is not an indirect one,
e.g. via an effect on endothelial cells. Finally, we investigated the effect of HGF/SF on dissemination of c-MET-transduced Ramos cells. In
response to HGF/SF, c-MET-transduced Ramos cells showed an increased migration through Matrigel in Boyden chambers compared to
wild-type and control-transduced Ramos cells. The dissemination pattern of c-MET-transduced cells did not differ from control cells in in vivo
experiments using SCID mice. Also no effect of HGF/SF administration could be documented, in contrast to the in vitro experiments. From our
experiments can be concluded that the HGF/SF–c-MET interaction only plays a minor role in the dissemination of human B-lymphoma cells.
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The Netherlandsfive cell lines tested were c-MET-positive). Furthermore, we found
that HGF/SF induced adhesion of c-MET-positive (but not of
c-MET-negative) human B-lymphoma cells to the extracellular
matrix (ECM) molecules fibronectin and collagen. Adhesion
appeared to be mediated by the integrins a4b1 and a5b1. In addi-
tion, HGF/SF promoted migration of c-MET-posit (and not of
c-MET-negative) human B-lymphoma cells through Matrigel in
Boyden chambers and invasion in rat fibroblast monolayers
(Weimar et al, 1997). These results suggest that HGF/SF-c-MET
interaction may promote dissemination of lymphoma cells in vivo.
Here, we investigated the tumorigenicity of both c-MET-positive
and c-MET-negative human B-lymphoma cells in severe
combined immune deficient (SCID) mice, with and without
administration of human HGF/SF. Human HGF/SF significantly
promoted dissemination of c-MET-positive lymphoma cells
(BJAB cells) and did not affect dissemination of c-MET-negative
tumour cells (Ramos cells). To test the hypothesis that HGF/SF
promotes the dissemination of c-MET-positive B-lymphoma cells,
we transduced c-MET-negative B-cells (Ramos) with the c-MET
gene and studied their capacity to migrate in vitro and in vivo. C-
MET transduction resulted in an increased migration of c-MET-
transduced Ramos cells through Matrigel in response to HGF/SF,
whereas HGF/SF did not affect migration of wild-type and
control-transduced cells. The dissemination pattern of c-MET-
transduced, control-transduced, or wild-type Ramos cells was
investigated in vivo by injecting the cells in SCID mice.
MATERIALS AND METHODS
Cells
B-cell lines (BJAB, Raji, Ramos and Daudi) and NIH3T3 cells
were obtained from the ATCC (Rockville, MD, USA). The c-
MET-transfected NIH3T3 cell line was a generous gift from Prof.
GF Vande Woude (National Cancer Institute, Frederick, MD,
USA). All cell lines were cultured in Iscove￿s modified Dulbecco￿s
medium (IMDM; Gibco-BRL, Gaithersburg, MD, USA), supple-
mented with 5% heat inactivated fetal calf serum (FCS;
BioWittaker, Brussels, Belgium), penicillin (100 U ml—1; Gibco-
BRL) and streptomycin (100 mg ml—1; Gibco-BRL).
Tumorigenicity establishment of B-lymphoma cells in
SCID mice
C.B-17 scid/scid (SCID) mice were bred and maintained at the
Animal Department of The Netherlands Cancer Institute. The
mice were kept in isolators under specific pathogen-free condi-
tions and used when 6—10 weeks old. All experiments were
approved by the Animal Experimental Advisory Board of The
Netherlands Cancer Institute.
Mice were injected intravenously (i.v.; in the tail vein) with
5 ´ 106 B-cell tumour cells. In the first pilot experiment HGF/SF
(5 mg per mouse) was obtained from R&D Systems, Abingdon,
UK (produced in Sf21 insect cells) and was mixed with the tumour
cells before i.v. injection, while in all other in vivo experiments,
HGF/SF was produced in our laboratory (see below), and was
injected subcutaneously (s.c.; into the right flank; 5 mg (or in one
experiment 25 mg) per mouse per day; 7 ´; starting on the day of
the i.v. tumour injection).
After 3—5 weeks, mice appeared ill (signs of paralysis, ovarian
tumour, loss of weight, etc.) and all mice in the same experiment
were sacrificed and examined. Organs were fixed (in 4%
formaldehyde), embedded in paraffin after which sections were
stained for human B-leucocytes (monoclonal mouse anti-human
leucocyte common antigen [LCA], No M701, Dakopats, Glostrup,
Denmark).
HGF/SF production
HGF/SF was produced by Spodoptera frugiperda 9 (Sf9) insect
cells using the baculo-gold-virus-producing system as described
previously (Yee et al, 1993; HGF/SF cDNA was a gift from Prof
T Nakamura). In short, Sf9 insect cells were infected with
baculovirus containing the HGF/SF gene, and secreted (±2 mg ml—1
as measured by enzyme-linked immunosorbent assay (ELISA)
biologically active HGF/SF (tested in proliferation assays and
colony assays) with human bone marrow cells on which HGF/SF
acts as a synergistic proliferative factor with other growth factors
(Weimar, 1998), tested in a proliferation assay with c-MET-trans-
fected NIH3T3 cells; tested in a scattering assay with MDCK cells
(Hordijk et al, 1997). HGF/SF in supernatant of the Sf9 cells was
purified using a heparin column and eluted with 1.5 M sodium
chloride. Usually, 5 mg HGF/SF was injected s.c. per mouse per
day, which contained 70 ng endotoxin. In some experiments
HGF/SF was denaturated (30 min autoclaved) to administer
exactly the same amount of endotoxin in both groups (the auto-
claved HGF/SF was no longer biologically active as tested in
colony assay with human bone marrow cells). Subcutaneous injec-
tions of 5 mg HGF/SF daily for 7 days did not affect the mice. No
illness or other dysfunctions were observed.
Proliferation assays
3H-thymidine incorporation assay
Five thousand cells were plated per well in a 96-well plate
(Greiner; flat bottom) in IMDM (Gibco-BRL, Gaithersburg, MD,
USA), supplemented with 5% heat inactivated FCS (BioWittaker,
Brussels, Belgium), penicillin (100 U ml—1; Gibco-BRL) and strep-
tomycin (100 mg ml—1; Gibco-BRL). After 1 day, the cells were
pulsed for 4 h with 3H-thymidine (0.5 mCi per well) and counted in
a b-plate counter (1205 betaplate“, Finland).
Colony formation assay
A total of 1 ´ 105 mononuclear human and murine bone marrow
cells were suspended in 1 ml of IMDM + L-glutamine (Gibco-
BRL), supplemented with 10% FCS (BioWittaker), P/S,
7.3  ´ 10—5 M a-monothioglycerol (Sigma, Zwijndrecht, The
Netherlands) and 0.36% agarose (SeaPlaque GTG; FMC,
Rockland, ME, USA) and were plated in triplicate in petri dishes
(35  ´ 10 mm Falcon/Becton Dickinson, Plymouth, UK). The
number of colonies (a colony is 20 cells or more) were scored after
2 weeks by an inverted microscope.
HGF/SF ELISA
HGF/SF was determined by a HGF-ELISA kit (Institute of
Immunology Co. Ltd, Tokyo, Japan). HGF/SF detection is based
upon a sandwich method using a solid phase coated anti-human
HGF/SF mouse monoclonal antibody and a peroxidase-labelled
anti-human HGF/SF mouse monoclonal antibody. Amounts from
0.1 ng ml—1 were reliably detected according to the linearity of the
standard curve.
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The c-MET coding sequence was cloned from the pMB1 plasmid
(generous gift from Prof. T Nakamura) by polymerase chain
reaction (PCR) with the following primers: 5¢ CGCGCTCGAGC-
CATGGAGGCCCCCGCTGTGCTTGCA; 3¢ GATCCCGGGCA-
CTATGATGTCTCCCAGAAGG.
The PCR product was cut with NcoI (introduced with PCR
primer; start codon) and SwaI (downstream of the stop-codon),
ligated in pSP73 (with Xho/EV), and after ± 140 bp exchanged
with wild-type cDNA (without PCR; with SstII and ClaI). c-MET
cDNA (4175 bp) was cut from pSP73 (with Xho/ScaI) and ligated
between the XhoI and the SnaBI site of the polylinker from the
plasmid LZRS-linker-IRES-EGFP (a modified version of GFP
with an enhanced expression (obtained from Clontech
Laboratories, Palo Alto, CA, USA) (Heemskerk et al, 1997), to
obtain the retroviral vector LZRS-c-MET-IRES-GFP, containing
LTR and Y packaging sequences from the Moloney murine
leukaemia virus (Mo-MuLV) as well as puromycin resistance
gene.
HGF/SF in dissemination of B-cells in SCID mice 45
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Figure 1 (A) Thymidine incorporation (of 4 hours) of c-MET transfected NIH3T3 cells (A-I) and wild-type NIH3T3 cells (A-II) with and without HGF/SF (5, 15
and 50 ng ml–1). Values are means from triplicates ± s.d. (B) Colony formation of 1 ´ 105 human and murine mononuclear bone marrow cells in 2 weeks. Values
are mean number of colonies ± s.d. from triplicate culturesThe retroviral packaging Phoenix cells (generous gift from Dr
GP Nolan, Stanford University School of Medicine, CA, USA)
were transfected using the calcium phosphate transfection system
(Gibco-BRL, Breda, The Netherlands) with the c-MET containing
vector. Transfected cells were selected by addition of puromycin
(2.5 mg ml—1; Clontech Laboratories) at day 2. Ten to 14 days after
transfection, 6 ´ 106 cells were plated per 10-cm petri dish in 10
ml complete medium without pyromycin. The next day, the
medium was refreshed and on the following day retroviral super-
natant was harvested, centrifuged and frozen (—70°C) in aliquots.
Control viral supernatant was collected from cells that had been
transfected with the control vector (LZRS-IRES-GFP). Viral
supernatants (c-MET-GFP and GFP) were preincubated with
dotap (10 mg ml—1; Boehringer Mannheim, Mannheim, Germany)
on ice for 10 min, and incubated overnight with Ramos cells. After
5 days the transduced Ramos cells were sorted by FACS-STAR on
GFP expression (Mann et al, 1983; Kinsella and Nolan, 1996).
c-MET-staining of transduced cells
Cytospins were prepared of transduced and wild-type Ramos cells,
which were fixed with methanol and stained with a polyclonal
antibody directed to the last 28 C-terminal amino acids of c-MET
(C-28; Santa Cruz; 250 ng ml—1) or as a control with a polyclonal
control IgG (used at the same concentration as C-28: 250 ng ml—1;
Southern Biotechnology Associates Inc, Birmingham, AL, USA).
Cytospins were washed and incubated with fluorescein isothio-
cyanate (FITC)-labelled goat anti-rabbit. After washing, cells were
examined for c-MET staining with a fluorescent microscope.
In vitro invasion assay
Boyden chambers (6-well plates; Becton Dickinson) were used to
assess tumour cell invasiveness as described previously by Albini
et al (1987). Upper and lower chambers of the Boyden chambers
were separated by Matrigel-coated filters with 8-mm pores. After
rehydration of the Matrigel in IMDM + 0.1% bovine serum
albumin (BSA), cells (5 ´ 105) were seeded in the upper chambers
in 1.5 ml culture medium (IMDM containing L-glutamin, supple-
mented with 5% FCS and P/S). HGF/SF (25 ng ml—1; produced by
COH cells; gift from Prof. T Nakamura, Division of Biochemistry,
Biomedical Research Center, Osaka University Medical School,
Japan) was added to the lower chambers in 2.6 ml of the same
culture medium as present in the upper wells. The chambers were
incubated overnight at 37°C. All cells that had migrated from the
upper to the bottom of the lower chamber were counted using an
inverted light microscope with a 20 ´ ocular.
Statistical analysis
Differences in the number of organs of SCID mice invaded by
tumour cells between the different groups was determined using
the c2 test. Differences were considered to be statistically signifi-
cant at the 5% level. Means ± standard deviation (s.d.) were calcu-
lated from proliferation tests.
RESULTS
Production of HGF/SF and effect on SCID mice
HGF/SF was produced by Sf9 insect cells using the baculo-gold-
virus-producing system. This HGF/SF was used for the in vivo
experiments described below. First the biological activity of puri-
fied HGF/SF was tested in the presence of FCS to enhance the
conversion of pro-HGF/SF into active HGF/SF. HGF/SF promoted
the proliferation of NIH3T3-cells, transfected with c-MET, in a
dose-dependent manner (Figure 1A). Furthermore, purified
HGF/SF promoted colony formation of murine and human
haemopoietic progenitor cells. HGF/SF acted synergistic with
granulocyte-macrophage colony-stimulating factor (GM-CSF)
and interleukin (IL)-3 (Figure 1B). Purified HGF/SF induced scat-
tering of MDCK (Hordijk et al, 1997). The biological activity of
the Sf9-derived HGF/SF was similar to recombinant HGF/SF
produced by Dr T Nakamura (Figure 1B). The purified HGF/SF
from the Sf9 cells was applied for further in vivo studies.
HGF/SF injected s.c. in normal Balb/c mice did not induce
marked toxicity in these mice as measured by changes in activity
of the mice, haematological cell counts or survival (n = 20; until
day 30; results not shown). Also, HGF/SF (5 mg once a day s.c. for
7 days) did not induce toxicity in SCID mice (n = 4; observations
for up to 2 months; results not shown).
Expression of c-Met, HGF/SF production cell lines
c-MET expression was determined in the lymphoma cell lines
Daudi, Ramos and BJAB using reverse transcription PCR (RT-
PCR). c-MET mRNA was detected in the cell line BJAB and not
in the cell lines Daudi and Ramos (Weimar et al, 1997). HGF/SF
could not be detected (by ELISA) in the supernatant of these three
cell lines after 1—3 days of culture (results not shown). The c-
MET-negative Ramos cell line was transduced with a retroviral
vector, containing either green fluorescence protein (Ramos-GFP)
or the c-MET—IRES—GFP (Ramos-c-MET—GFP) sequence. After
selection, c-MET-transduced Ramos cells could be identified by
both green fluorescence expression as well as by c-MET protein
expression (Figures 2 and 3). The biological behaviour of the
transfected cells differed from the wild-type Ramos (wtRamos)
cells as determined in an in vitro migration assay. In comparison to
wtRamos cells or control-transduced (with GFP) Ramos cells, the
c-MET—GFP-transduced Ramos cells migrated better in response
to HGF/SF (Table 1).
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Table 1 Effect of HGF/SF on migration through Matrigel of c-MET-
transduced RAMOS cells
Number of migrated cells
Experiment RAMOS cells Without HGF/SF With HGF/SF
1 wild-type 267 225
GFP 339 385
c-MET/GFP 301 542
2 wild-type 189 194
GFP 213 225
c-MET/GFP 202 796
Ramos cells (5 ´ 105) wild-type, control-transduced (with GFP alone), and 
c-MET-IRES-GFP-transduced (c-MET/GFP) were mounted in 1.5 ml culture
medium in the upper wells of Boyden chambers. Upper and lower wells were
separated by Matrigel-coated membranes with 8-mm pores. In the lower
chambers 2.6 ml culture medium was present with or without HGF/SF 
(25 ng ml–1). After 16 h, all cells that had migrated to the bottom of the lower
well were counted with a 20 ´ ocular of an inverted microscope.These in vitro results suggest that the c-MET—HGF/SF inter-
action promotes dissemination of lymphoma cells in vivo, like has
been observed for transfected NIH3T3 cells and several epithelial
cells (Cooper et al, 1986; Stoker et al, 1987; Iyer et al, 1989; Rong
et al, 1992, 1993, 1994; Liu et al, 1992; Giordano et al, 1993;
Bellusci et al, 1994).
Effect of HGF/SF on tumorigenicity of c-MET-positive B-
lymphoma cells in SCID mice
SCID mice were injected i.v. with 5 ´ 106 BJAB cells. HGF/SF
was administered s.c. once daily for 7 days. BJAB cells gave
tumours in lymph nodes, kidneys, lungs and gonads (Table 2).
More mice developed tumours in the different organs when treated
with HGF/SF (5 mg per day). Pooling of the six different organs
that were investigated of the four mice per group, showed that
metastases were formed in 5/24 organs of the mice that were not
treated with HGF/SF versus 11/24 organs of the mice that were
treated with HGF/SF (mice got ill and were sacrificed 32 days
after tumour inoculation) in experiment 1, and that metastases
were formed in 6/24 organs of the mice that were not treated with
HGF/SF versus 11/24 organs of mice that were treated with
HGF/SF (mice got ill and were sacrificed at day 28 and 29) in
experiment 2. Adding the results from the two experiments
together revealed a significant difference (P = 0.018) in the
number of organs with metastases of the mice treated with
HGF/SF (5 mg per day) and control mice. In the two experiments,
HGF/SF treatment not only promoted dissemination in more mice,
but HGF/SF-treated mice also had more lymph node metastases
(19 versus eight). Increasing the dose of HGF/SF (from 5 to 25 mg
per day ´ 7 days) did not result in an increased tumorigenicity.
Mice treated with 25 mg per day HGF/SF did not have a different
dissemination pattern from the control mice (Table 2).
Effect of HGF/SF on tumorigenicity of c-MET-negative
B-lymphoma cells in SCID mice
As a control to prove that HGF/SF increases tumorigenicity of
c-MET-positive cells by an effect of HGF/SF on the tumour cells
and not on e.g. endothelial or other cells leading to an increased
invasion, we studied the effect of administration of HGF/SF on the
dissemination pattern of c-MET-negative tumours in SCID mice.
The Daudi and Ramos cell lines did not express c-MET as detected
by RT-PCR. Mice were injected i.v. with 5 ´ 106 tumour cells and
5 mg HGF/SF per day was injected s.c. for 7 days. All mice
injected with Daudi cells got sick and were sacrificed at day 32,
and mice injected with Ramos cells at day 30. One of the symp-
toms was paralysis of the hind legs. This symptom was observed in
2/8 mice injected with Daudi cells (one mouse in HGF/SF-treated
group and one in the control group) and in 3/8 mice injected with
Ramos cells (one mouse in HGF/SF-treated group and two in the
control group). Comparing control mice with HGF/SF-treated
HGF/SF in dissemination of B-cells in SCID mice 47
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Table 2 Effect of HGF/SF on dissemination pattern of BJAB (c-MET+) cells in SCID mice
Experiment Organs Without HGF/SFa With HGF/SFa
1( 5 mg day–1 ´ 7)
Lymph nodesb 2/4 3/4
Kidney 2/4 4/4
Lung 1/4 4/4
Liver 0/4 0/4
Spleen 0/4 0/4
Gonads 0/4 0/4
Total 5/24 11/24
2( 5 mg day–1 ´ 7) 25 mg day–1 ´ 7)
Lymph nodesb 3/4 4/4 2/4
Kidney 2/4 3/4 2/4
Lung 0/4 0/4 0/4
Liver 0/4 0/4 0/4
Spleen 0/4 0/4 0/4
Gonads 1/4 4/4 0/4
Total 6/24 11/24 4/24c
1+2 Lymph nodesb 5/8 7/8
Kidney 4/8 7/8
Lung 1/8 4/8
Liver 0/8 0/8
Spleen 0/8 0/8
Gonads 1/8 4/8
Total 11/48 22/48d
Mice were injected i.v. with 5 ´ 106 BJAB cells. Either salt or HGF/SF (5 or 25 mg day–1) was administered each
day s.c. for 7 days to the mice, starting at the day of tumour injection. ax/y indicates the number of mice with the
indicated phenomenon (x) out of the number of mice in each group (y). bThe lymph nodes that were involved
included: axillary, brachial, poplitial, lumbal, inguinal, caudal and renal; not indicated is the number of lymph nodes
in which metastases were formed. cIndicates that the number of organs with metastases is significantly decreased
(P = 0.029) compared to the number observed with 5 mg HGF/SF per day and is not significantly different 
(P = 0.0477) from the number observed without HGF/SF. dindicates that the number of organs with metastases is
significantly different (P = 0.018) from the number obtained without HGF/SF.mice revealed that HGF/SF treatment did not promote dissemina-
tion of these two cell lines. There is a tendency that with these cell
lines, HGF/SF treatment results in fewer tumours; however, these
differences are not significant (P = 0.350 for Daudi cells and P =
0.353 for Ramos cells; Table 3). These data suggest that HGF/SF
did not affect dissemination of lymphoma cells by an indirect
effect on e.g. endothelial cells.
Tumorigenicity after c-MET transduction of c-MET-
negative B-lymphoma cells
To strengthen our hypothesis that HGF/SF increased tumori-
genicity of c-MET-positive cells, we studied the effect of HGF/SF
on tumorigenicity of the c-MET-transduced Ramos cells (Ramos-
c-MET), compared to control-transduced cells (Ramos-GFP),
which gave promising results in the in vitro assay (Table 1).
Normal HGF/SF (5 mg per mouse per day) and denaturated
(30 min autoclaved) HGF/SF were injected s.c. once a day for 7
days. Denaturated HGF/SF was injected instead of salt to exclude
the possibility that a low level of endotoxin present in the HGF/SF
might influence tumorigenicity of the tumour cells. Denaturated
HGF/SF did not have any biological effect in colony assays (data
not shown).
Two experiments were performed with four SCID mice per
group (Ramos-GFP ± HGF/SF and Ramos-c-MET—GFP ± HGF/
SF). Survival did not differ between the four groups; Ramos-GFP
(without HGF/SF) 31 ± 1 days, Ramos-GFP (with HGF/SF) 33 ± 2
days, Ramos-c-MET—GFP (without HGF/SF) 29 ± 1 days, and
Ramos-c-MET—GFP (with HGF/SF) 32± 2 days. Twelve out of 16
mice were sacrificed when the hind legs became paralysed. In the
second experiments almost all mice got sick on day 30 (paralysis
16/16 mice) and all mice were killed on day 31. The results of the
two experiments with regard to dissemination are shown in Table
4. c-MET transduction did not result in a different dissemination
pattern. HGF/SF treatment seemed to promote dissemination of
Ramos-GFP cells, but the increase was not significant (P = 0.210).
HGF/SF treatment also did not significantly affect dissemination
of Ramos-c-MET cells in vivo (P = 0.142; Table 4), in contrast to
the results of these cells in the in vitro experiments (Table 1).
DISCUSSION
c-MET is expressed on immature B-cells, such as CD38+CD77+
tonsillar B-cells and CD19+CD20— B-cells, and not on mature B-
cells. c-MET expression can be up-regulated by activation of
mature B-cells using stimuli such as CD40-ligand, phorbol 12-
myristate 13-acetate (PMA) or Epstein—Barr virus (EBV) infection
(van der Voort et al, 1997; Weimar et al, 1997). We have previ-
ously shown that c-MET is expressed in lymph node samples from
non-Hodgkin￿s lymphoma (NHL) and Hodgkin￿s disease patients
(Weimar et al, 1997). c-MET expression was found in centroblasts
of follicular centre cell NHL (8/11 cases were positive), in
centroblasts of large B-cell NHL (7/17 cases were positive), and
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Table 3 Effect of HGF/SF on dissemination of c-MET-negative lymphoma
cell lines in SCID mice
Cell line Organs Without HGF/SFa *With HGF/SFa
Daudi Lymph nodesb 3/4 1/4
Kidney 3/4 3/4
Lung 0/4 0/4
Liver 0/4 0/4
Spleen 0/4 0/4
Ovary 3/4 2/4
Total 9/24 6/24c
Ramos Lymph nodesb 0/4 0/4
Kidney 2/4 0/4
Lung 0/4 0/4
Liver 3/4 2/4
Spleen 4/4 4/4
Ovary 1/2 1/2
Total 10/22 7/22c
Mice (all females) were injected i.v. with 5 ´ 106 cells. Either salt or HGF/SF
(5 mg day–1) was administered each day s.c. for 7 days to the mice, starting at
the day of tumour injection. Paralysis was present in the hind paws. 
ax/y indicates the number of mice with the indicated phenomenon (x) out of
the number of mice in each group (y). bThe lymph nodes that were involved
included axillary, brachial, poplitial, lumbal, inguinal, caudal and renal; not
indicated is the number of lymph nodes in which metastases were formed.
cAddition of HGF/SF did not result in a significant difference in the number of
of mice with metastases in indicated organs: with Daudi-cells: P = 0.350; with
Ramos-cells: P = 0.353.
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Figure 2 Flow cytometric analysis of GFP and c-MET–GFP in wild-type (baseline green fluorescence) and transduced (high expression of green fluorescence)
Ramos cells. (A) Wild-type Ramos cells; (B) GFP (control)-transduced Ramos cells; (C) c-MET–GFP-transduced Ramos cellsin 1/3 samples of Burkitt￿s lymphoma. c-MET expression in
Hodgkin￿s disease seemed to be correlated with EBV-expression
(c-MET was expressed in 6/8 EBV positive samples, and in none
of the 10 EBV-negative samples), which is in concordance with
the previously obtained results that EBV can induce c-MET
expression.
Several lymphoma cell lines express c-MET (J￿cker et al, 1994;
van der Voort et al, 1997; Weimar et al, 1997). We found c-MET
expression in 2/5 human B-lymphoma cell lines tested (BJAB and
Raji were positive; Ramos, Daudi and Jiyoye were negative)
(Weimar et al, 1997).
The c-MET ligand HGF/SF is produced by mesenchymal cells,
including tonsillar stromal cells and follicular dendritic cells (Van
der Voort et al, 1997). For this study we used the c-MET-positive
cell line BJAB and the c-MET-negative cell lines Ramos and
Daudi for our in vivo experiments, since other investigators have
also identified these cell lines as c-MET-positive and -negative
respectively (van der Voort et al, 1997; J￿cker et al, 1994). We
have previously observed that HGF/SF stimulated the migration
and invasion of c-MET-positive cell lines, but not of c-MET-
negative cell lines (Weimar et al, 1997). In the present study, these
results were confirmed. Transduction of Ramos cells with c-MET
markedly promoted migration of the transduced cells in response
to HGF/SF in an in vitro assay. A response to HGF/SF was only
observed when Ramos cells were transduced with c-MET gene
(not in control-transduced cells and wild-type cells), suggesting
that overexpression of the c-MET gene plays a role in the active
migration of lymphoma cells. In a control experiment we deter-
mined the effect of HGF/SF on the proliferation of the human B-
lymphoma cell lines. None of the cell lines that we have used for
our studies (BJAB, Daudi, Ramos and c-MET-transduced Ramos
cells) showed an altered proliferation by addition of HGF/SF
(excluding the possibility that instead of migration, proliferation
had been stimulated).
We could not detect the protein HGF/SF by ELISA in the super-
natant of the cell lines. Nakamura et al. (1994) have studied 46
lymphoma B-cell lines and could detect production of HGF/SF in
only two B-cell lines. Similar to our studies, the cell lines BJAB,
RAMOS and Daudi did not produce HGF/SF. Studies in the
normal environment of normal B-cells demonstrated that HGF/SF
is produced by stromal cells and suggest that HGF/SF is produced
by follicular dendritic cells (van der Voort et al, 1997). These data
suggest that any effect of HGF/SF on B-cells is mostly due to
paracrine production of HGF/SF in the microenvironment of the
tumour. Based on these data and the effect of HGF/SF on migra-
tion of B-cells in vitro described above, we started these series of
experiments to study the effect of (over)expression of c-MET on
the dissemination pattern of human lymphoma cells in SCID mice.
Murine and human HGF/SF are highly homologous, and human
HGF/SF efficiently activates the murine MET receptor, but murine
HGF/SF does not appear to activate efficiently the human MET
receptor (Bhargava et al, 1992; Rong et al, 1992, 1994). Therefore,
human HGF/SF was exogeneously administered to the mice.
After i.v. administration, liver and kidney are the most active
organs sequestering HGF/SF, but detectable levels of radioiodinated
HGF/SF could also be recovered from other highly perfused organs
such as spleen and adrenals (Appasamy et al, 1993; Zioncheck et al,
1994). The initial half-life of HGF/SF is 3 min and the elimination
half-life is approximately 83—114 min. No major toxicities have
been reported after i.v. administration of HGF/SF in rats or dogs.
The doses applied in this study were equivalent to doses applied in
other murine models. In these models, HGF/SF at a dose of 100 mg
kg—1 protected against renal failure or liver cirrhosis (Matsudo et al,
1995; Ueno et al, 1996; Matsudo et al, 1997).
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Table 4 Tumorigenicity of c-MET transduced Ramos cells in SCID mice
Organs Transduction Without active HGF/SFa With HGF/SFa
Lymph nodesb GFP 2/8 2/8
c-MET/GFP 3/8 1/8
Kidney GFP 1/8 3/8
c-MET/GFP 2/8 0/8
Lung GFP 0/8 0/8
c-MET/GFP 0/8 0/8
Liver GFP 6/8 7/8
c-MET/GFP 5/8 7/8
Spleen GFP 7/8 8/8
c-MET/GFP 8/8 5/8
Gonads GFP 0/8 2/8
c-MET/GFP 4/8 2/8
Total GFP 16/48 22/48c
c-MET/GFP 22/48 15/48c
Mice (50% females and 50% males per group) were injected i.v. with 5 ´ 106 cells. Either inactivated
HGF/SF (denaturated) or active HGF/SF (5 mg day–1) was administered each day s.c. for 7 days to the mice,
starting at the day of tumour injection. Paralysis was present in the hind paws. ax/y indicates the number of
mice with the indicated phenomenon (x) out of the number of mice in each group (y). bThe lymph nodes that
were involved included: axillary, brachial, poplitial, lumbal, inguinal, caudal and renal; not indicated is the
number of lymph nodes in which metastases were formed. cAddition of HGF/SF did not result in a significant
difference in the number of organs with metastases: with Daudi-cells: P = 0.350; with Ramos-cells: 
P = 0.353.50 IS Weimar et al
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Figure 3 Expression of c-MET in transduced Ramos B-lymphoma cells: Cytospins of c-MET–GFP transduced Ramos cells (A) and, as a control, GFP
transduced Ramos cells (B) were incubated with a polyclonal (rabbit) antibody directed to the C-terminal part of c-MET (C-28, Santa Cruz), and as a second
step with FITC-labelled goat anti-rabbitSCID mice have been used succesfully to study dissemination of
human lymphoma cells (Cesano et al, 1991; Mule et al, 1992; Walter
et al, 1992; de Kroon et al, 1994; Schwartz et al, 1995; Stroeken et
al, 1998). Human B-lymphoma cells (e.g. Ramos and Nalm-6) can
bind via their a4b1 integins to murine VCAM-1 molecules, because
this interaction is not species-specific (Renz et al, 1994; Tsuzuki et
al, 1998). Since we have previously observed that HGF/SF induced
adhesion of human c-MET-positive B-cells to fibronectin probably
via activation of a4b1 integrins (Weimar et al, 1997), we speculated
that i.v. injected human c-MET-positive B-cells could adhere to the
murine endothelial cells of the SCID-mice via VCAM-1 molecules
expressed on these endothelial cells. We hypothesized that addition
of human HGF/SF would increase dissemination (via activation of
a4b1 integins on the c-MET-positive human B-cells).
In our experiments, exogenous administered HGF/SF signifi-
cantly promoted the dissemination of (i.v. injected) BJAB cells;
more mice developed tumours and more lymph node metastases
were scored (Table 2). These results suggested an effect of
HGF/SF on dissemination of c-MET-positive BJAB cells. HGF/SF
is known to have multiple activities on vascular endothelial cells.
Following stimulation of endothelial cell line (ECV304) with
HGF/SF, adherence of colon carcinoma cells to the activated
endothelial cells increased. Adhesion was mediated by CD44
receptors, since adhesion could be blocked by anti-CD44 anti-
bodies and HGF/SF up-regulated protein expression of CD44
(Hiscox and Jiang, 1997). Furthermore, HGF/SF promotes the
growth of endothelial cells (Bussolino, 1992; Nakamura et al,
1996) and motility of endothelial cells (Bussolino, 1992). To
exclude the possibility that the observed effects of HGF/SF on the
c-MET-positive BJAB cell line was attributable to an effect of
HGF/SF on vascular endothelial cells, we also used the c-MET-
negative cell lines (Daudi and Ramos). Since HGF/SF did not
affect dissemination of these c-MET-negative cell lines, the
observed effect of HGF/SF in promoting dissemination of BJAB
cells in SCID mice is probably not via an effect on vascular
endothelial cells (Table 3).
Overexpression of c-MET has been well documented in various
tumours, ranging from melanoma, colectoral carcinoma, thyroid
carcinoma, osteosarcoma to leukaemia and lymphoma (Di Renzo et
al, 1992, 1995; Liu et al, 1992; Natali et al, 1993; J￿cker et al, 1994;
Ferracini et al, 1995). The role of overexpression of c-MET on
tumorigenicity has been reported for several tumour cell lines.
Transfection of murine c-MET in NIH3T3 cells promoted s.c.
tumour growth in athymic nude mice, while transfection of human
c-MET did not induce tumorigenicity (Rong et al, 1992; Jeffers et
al, 1996). The authors explain the differences by the fact that
murine HGF/SF does not appropriately stimulate the human 
c-MET. Co-transfection of human HGF/SF in human c-MET-
positive NIH3T3 cells did induce tumorigenicity in 89% of the
mice. The same group of investigators have studied the effect of 
c-MET overexpression in the mouse mammary tumour C127
(Jeffers et al, 1996a, 1996b). Transfection of neither c-MET nor
HGF/SF promoted tumour formation in mice, while co-transfection
of both genes markedly induced s.c. tumors. Based on these data
we administered human HGF/SF to our mice injected with human
c-MET-transduced Ramos cells. In our experiments with 
c-MET-transduced Ramos cells, c-MET transduction itself did not
affect invasion of organs by lymphoma cells. This could be due to
the lack of human HGF/SF. However, also the administration of
human HGF/SF did not have any effect on tumorigenicity of the 
c-MET-transduced Ramos cells. HGF/SF administration also did
not affect survival times of the mice. Although we can not exclude
the possibility that co-transfection of human HGF/SF in these 
c-MET-transduced cells, creating an autocrine production of
HGF/SF, might have different outcomes, our data indicate that 
the c-MET—HGF/SF interaction only plays a minor role in
tumorigenicity of human B-cell lymphoma cell lines in SCID mice.
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